Global Ivosidenib Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Ivosidenib Drugs Market Research Report 2024
Ivosidenib is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer.
According to Mr Accuracy reports new survey, global Ivosidenib Drugs market is projected to reach US$ 238.5 million in 2029, increasing from US$ 175.3 million in 2022, with the CAGR of 4.8% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Ivosidenib Drugs market research.
Ivosidenib's market driver is its efficacy in treating relapsed or refractory acute myeloid leukemia (AML) with IDH1 mutations. It inhibits the mutated IDH1 enzyme, leading to remission. The niche target population and limited treatment options contribute to its growth. However, challenges include potential side effects, the need for genetic testing to identify eligible patients, and competition from other AML therapies. Despite challenges, Ivosidenib's promising results and ongoing research in AML with IDH1 mutations present opportunities for market expansion.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Ivosidenib Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Servier Pharmaceuticals
Segment by Type
60 Tablets
30 Tablets
Hospital
Pharmacy
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Ivosidenib Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Ivosidenib Drugs market is projected to reach US$ 238.5 million in 2029, increasing from US$ 175.3 million in 2022, with the CAGR of 4.8% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Ivosidenib Drugs market research.
Ivosidenib's market driver is its efficacy in treating relapsed or refractory acute myeloid leukemia (AML) with IDH1 mutations. It inhibits the mutated IDH1 enzyme, leading to remission. The niche target population and limited treatment options contribute to its growth. However, challenges include potential side effects, the need for genetic testing to identify eligible patients, and competition from other AML therapies. Despite challenges, Ivosidenib's promising results and ongoing research in AML with IDH1 mutations present opportunities for market expansion.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Ivosidenib Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Servier Pharmaceuticals
Segment by Type
60 Tablets
30 Tablets
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Ivosidenib Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices